Radionuclide Therapy of Bone Metastases Using Rhenium-188 Hydroxyethylidene Diphosphonate

  • Jan Bucerius
  • Holger Palmedo
  • Hans-Jürgen Biersack
Part of the Medical Radiology book series (MEDRAD)


Many solid malignant tumors, mainly prostate, breast, and lung cancer, generate bone metastases throughout the course of disease. They can lead to serious complications of which chronic pain syndrome is the most important and frequent one, having a negative impact on quality of life and the social environment of the patient. Radionuclide therapy of bone metastases was introduced decades ago as a therapeutic option for patients suffering from painful bone metastases. Out of several radiopharmaceuticals, which are or have been used for this purpose, Rhenium-188 hydroxyethylidene diphosphonate (Re-188 HEDP) is a relatively new and, mainly because of its physical properties, attractive alternative. It localizes in skeletal metastases and emits beta particles and was previously shown to be beneficial for the palliative treatment of metastatic bone disease. In this chapter, the methodology of Re-188 HEDP treatment as well as clinical studies and new treatment strategies involving Re-188 HEDP are discussed in order to provide a detailed overview of this treatment option for patients suffering from bone metastases.


Bone Metastasis Prostate Cancer Patient Skeletal Metastasis Radionuclide Therapy Karnofsky Performance Scale 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Besson JM, Chaouch A (1987) Peripheral and spinal mechanisms of nociception. Physiol Rev 67:167–186Google Scholar
  2. Biersack HJ, Palmedo H, Andris H, Rogenhofer S, Knapp FF, Guhlke S, Ezziddin S, Bucerius J, von Mallek D (2011) Palliation and survival after repeated 188Re-HEDP therapy of hormone-refractory bone metastases of prostate cancer: a retrospective analysis. J Nucl Med 52:1721–1726PubMedCrossRefGoogle Scholar
  3. Blake GM, Zivanovic MA, McEwan AJ, Ackery DM (1986) Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 12:447–454PubMedGoogle Scholar
  4. Blake GM, Zivanovic MA, McEwan AJ, Batty VB, Ackery DM (1987) 89Sr radionuclide therapy: dosimetry and haematological toxicity in two patients with metastasising prostatic carcinoma. Eur J Nucl Med 13:41–46PubMedCrossRefGoogle Scholar
  5. Blake GM, Zivanovic MA, Lewington VJ (1989a) Measurements of the strontium plasma clearance rate in patients receiving Sr89 radionuclide therapy. Eur J Nucl Med 15:780–783PubMedGoogle Scholar
  6. Blake GM, Wood JF, Wood PJ, Zivanovic MA, Lewington VJ (1989b) 89Sr therapy: strontium plasma clearance in disseminated prostatic carcinoma. Eur J Nucl Med 15:49–54PubMedGoogle Scholar
  7. Cheng A, Chen S, Zhang Y, Yin D, Dong M (2011) The tolerance and therapeutic efficacy of rhenium-188 hydroxyethylidene diphosphonate in advanced cancer patients with painful osseous metastases. Cancer Biother Radiopharm 26:237–244PubMedCrossRefGoogle Scholar
  8. Cserhati P (1987) Metastatic disease in breast cancer. J Clin Oncol 21:1235–1241Google Scholar
  9. de Klerk JMH, van Dijk A, van het Schip AD, Zonnenberg BA (1992) van Rijk PP Pharmacokinetics of Rhenium-186 after administration of Rhenium-186-HEDP to patients with bone metastases. J Nucl Med 33:646–651PubMedGoogle Scholar
  10. Dunning WF (1963) Prostate cancer in the rat. Natl Cancer Inst Monogr 12:351–369PubMedGoogle Scholar
  11. Eisenberger MA, Simon R, O’Dwyer PJ, Wittes RE, Friedman MA (1985) A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3:827–841PubMedGoogle Scholar
  12. El-Mabhouh AA, Mercer JR (2008) 188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases. Eur J Nucl Med Mol Imaging 35:1240–1248PubMedCrossRefGoogle Scholar
  13. Ferro-Flores G (2008) Arteaga de Murphy C. Pharmacokinetics and dosimetry of 188 Re-pharmaceuticals. Adv Drug Deliv Rev 60:1389–1401PubMedCrossRefGoogle Scholar
  14. Foley KM, Arbit E (1989) The management of cancer pain. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 3rd edn. Lippincott, Philadelphia, pp 2064–2087Google Scholar
  15. Geldof AA, de Rooij L, Versteegh RT, Newling DW, Teule GJ (1999) Combination 186Re-HEDP and cisplatin supra-additive treatment effects in prostate cancer cells. J Nucl Med 40:667–671PubMedGoogle Scholar
  16. Holmes RA (1992) [153Sm] EDTMP: a potential therapy for bone cancer pain. Semin Nucl Med 22:41–45PubMedCrossRefGoogle Scholar
  17. Hsieh BT, Hsieh JF, Tsai SC, Lin WY, Wang SJ, Ting G (1999) Comparison of various rhenium-188-labeled diphosphonates for the treatment of bone metastases. Nucl Med Biol 26:973–976PubMedCrossRefGoogle Scholar
  18. Isaacs JT, Yu GW, Coffey DS (1981) The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: the MAT LyLu tumor. Invest Urol 19:20–23PubMedGoogle Scholar
  19. Isaacs JT, Isaacs WB, Feitz WF, Scheres J (1986) Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 9:261–281PubMedCrossRefGoogle Scholar
  20. Jacobs SC (1983) Spread of prostatic cancer to bone. Urology 21:337–344Google Scholar
  21. Kaplan E, Fels IG, Kotlowski BR (1960) Therapy of carcinoma of the prostate metastatic to bone with P-32 labeled condensed phosphate. J Nucl Med 1:1–13Google Scholar
  22. Ketring AR (1987) 153Sm-EDTMP and 186Re-HEDP as bone therapeutic radiopharmaceuticals. Nucl Med Biol 14:223–232Google Scholar
  23. Kutzner J, Dähnert W, Schreyer T, Grimm W, Brod KH, Becker M (1981) Yttrium-90 zur Schmerztherapie von Knochenmetastasen. Nuklearmedizin 20:229–235PubMedGoogle Scholar
  24. Lam MGEH, Bosma TB, van Rijk PP, Zonnenberg BA (2009) 188Re-HEDP combined with capecitabine in hormone-refractory prostate cancer patients with bone metastases: a phase I safety and toxicity study. Eur J Nucl Med Mol Imaging 36:1425–1433PubMedCentralPubMedCrossRefGoogle Scholar
  25. Lewington VJ (1993) Targeted radionuclide therapy for bone metastases. Eur J Nucl Med 20:66–74PubMedCrossRefGoogle Scholar
  26. Li S, Liu J, Zhang H, Tian M, Wang J, Zheng X (2001) Rhenium-188 HEDP to treat painful bone metastases. Clin Nucl Med 26:919–922PubMedCrossRefGoogle Scholar
  27. Liepe K, Hliscs R, Kropp J, Grüning T, Runge R, Koch R, Knapp FF Jr, Franke WG (2000) Rhenium-188-HEDP in the palliative treatment of bone metastases. Cancer Biother Radiopharm 15:261–265PubMedCrossRefGoogle Scholar
  28. Liepe K, Hliscs R, Kropp J, Runge R, Knapp FF Jr, Franke WG (2003a) Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. J Nucl Med 44:953–960PubMedGoogle Scholar
  29. Liepe K, Kropp J, Runge R, Kotzerke J (2003b) Therpeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br J Cancer 89:625–629PubMedCentralPubMedCrossRefGoogle Scholar
  30. Liepe K, Runge R, Kotzerke J (2005a) The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J Cancer Res Clin Oncol 131:60–66PubMedGoogle Scholar
  31. Liepe K, Runge R, Kotzerke J (2005b) Systemic radionuclide therapy in pain palliation. Am J Hosp Palliat Care 22:457–464PubMedCrossRefGoogle Scholar
  32. Liepe K, Geidel HH, Bergmann R, Haase M, Runge R, Kotzerke J (2009) Autoradiographic studies of rhenium-188-hydroxyethylidine diphosphonate in normal skeleton and osteoblastic bone metastases in a rat model of metastatic prostate cancer. Nucl Med Commun 30:693–699PubMedCrossRefGoogle Scholar
  33. Lin WY, Lin CP, Yeh SJ, Hsieh BT, Tsai ZT, Ting G, Yen TC, Wang SJ, Knapp FF Jr, Stabin MG (1997) Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases. Eur J Nucl Med 24:590–595PubMedGoogle Scholar
  34. Maxon HR 3rd, Schroder LE, Thomas SR, Hertzberg VS, Deutsch EA, Scher HI, Samaratunga RC, Libson KF, Williams CC, Moulton JS, Schneider HJ (1990) Re-186(Sn)HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology 176:155–159PubMedCrossRefGoogle Scholar
  35. Maxon HR 3rd, Schroder LE, Hertzberg VS, Thomas SR, Englaro EE, Samaratunga R, Smith H, Moulton JS, Williams CC, Ehrhardt GJ, Schneider HJ (1991) Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo. J Nucl Med 32:1877–1881PubMedGoogle Scholar
  36. Maxon HR 3rd, Schroder LE, Washburn LC, Thomas SR, Samaratunga RC, Biniakiewicz D, Moulton JS, Cummings D, Ehrhardt GJ, Morris V (1998) Rhenium-188(Sn)HEDP for treatment of osseous metastases. J Nucl Med 39:659–663PubMedGoogle Scholar
  37. Mense S (1981) Sensitization of group IV muscle receptors to bradykinin by 5-hydroxytryptamine and prostaglandin E2. Brain Res 225:95–105PubMedGoogle Scholar
  38. Mundy GR, Martin TJ (eds) (1989) Pathophysiology of skeletal complications of cancer. In: Physiology and pharmacology of bone. Springer, Heidelberg, pp 641–44Google Scholar
  39. Nielsen OS, Munro AJ, Tannock IF (1991) Bone metastases: pathophysiology and management policy. J Clin Oncol 9:509–524Google Scholar
  40. Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Risse J, Grünwald F, Knapp FF, Biersack HJ (2000) Dose escalation study with rhenium-188 HEDP in prostate cancer patients with osseous metastases. Eur J Nucl Med 27:123–130PubMedCrossRefGoogle Scholar
  41. Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, Joe A, Roedel R, Fimmers R, Knapp FF Jr, Guhlke S, Biersack HJ (2003) Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 21:2869–2875PubMedCrossRefGoogle Scholar
  42. Paterson AHG (1987) Bone metastases in breast cancer, prostate cancer and myeloma. Bone 8(Suppl 1):17–22Google Scholar
  43. Poner A, Mertens W (1991) Strontium 89 in the treatment of metastatic prostate cancer. Can J Oncol 1:11–18Google Scholar
  44. Resch K (1991) Der entzündliche Gelenkschmerz. In: Rheuma und Schmerz. Zimmermann M, Zeidler H, Ehlers H (Hrsg.). Der Schmerz 5(1): 3–12Google Scholar
  45. Savio E, Gaudiano J, Robles AM, Balter H, Paolino A, López A, Hermida JC, De Marco E, Martinez G, Osinaga E, Knapp FF Jr (2001) Re-HEDP: pharmacokinetic characterization, clinical and dosimetric evaluation in osseous metastatic patients with two levels of radiopharmaceutical dose. BMC Nucl Med 1:2PubMedCentralPubMedCrossRefGoogle Scholar
  46. Schmidt RF (1991) Physiologie und Pathophysiologie der Schmerzentstehung und Schmerzverarbeitung im Bewegungssystem. In: Rheuma und Schmerz. Zimmermann M, Zeidler H, Ehlers H (Hrsg.). Der Schmerz 5(1): 13–28Google Scholar
  47. Singh A, Holmes RA, Farhangi M (1989) Human pharmacokinetics of Samarium-153 EDTMP in metastatic cancer. J Nucl Med 30:1814–1818PubMedGoogle Scholar
  48. Strumpf M (1993) Krebbsschmerz. In: Lehrbuch der Schmerztherapie. Zenz J, Jurna I (Hrsg). Wissenschaftliche Verlagsgesellschaft Stuttgart, pp 427–436Google Scholar
  49. Willis WD (1985) The pain system. Karger-Verlag, Basel, pp 341–388Google Scholar
  50. Zhang H, Tian M, Li S, Liu J, Tanada S, Endo K (2003) Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients. Cancer Biother Radiopharm 18:719–726PubMedCrossRefGoogle Scholar
  51. Zimmermann M (1984) Physiologie von Nozizeption und Schmerz. In: Zimmermann M, Handwerker HO (eds) Schmerz—Konzepte und ärztliches Handeln. Springer, Berlin, pp 1–43Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Jan Bucerius
    • 1
    • 2
    • 3
  • Holger Palmedo
    • 4
  • Hans-Jürgen Biersack
    • 5
  1. 1.Department of Nuclear MedicineMaastricht University Medical CenterMaastrichtThe Netherlands
  2. 2.Cardiovascular Research Institute Maastricht (CARIM)Maastricht University Medical CenterMaastrichtThe Netherlands
  3. 3.Department of Nuclear MedicineUniversity Hospital RWTH AachenAachenGermany
  4. 4.Department of Nuclear MedicineInstitute of Radiology and Nuclear Medicine Kaiserstraße BonnBonnGermany
  5. 5.Department of Nuclear MedicineUniversity of BonnBonnGermany

Personalised recommendations